Bio-thera Solutions, Ltd., Co.

Bio-thera Solutions, Ltd.

Weijia Tang

Shengfeng Li

Chao Qin

Xiaobin Deng

Jin-Chen Yu

Songnuan Tan

Yili Yang

Ziqiang Ou

Shenfeng Li

Xiaoyang Huang

Xian Peng

The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.

Compounds and methods for the treatment of TROP2 positive diseases

Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

Compounds and methods for the treatment of ERB B2/NEU positive diseases

Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

Maytansinoid derivatives

Growing community of inventors

Guangzhou, China

Weijia Tang